Drug Trial Radar · NCT00734578
Efficacy and Safety of SPD503 in Combination With Psychostimulants
Last checked: Nov 20, 2026Latest source record: Jun 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
461
Actual
Start
Sep 2, 2008
Primary completion
Dec 10, 2009
Study completion Dec 10, 2009
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Aug 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal, partial response to stimulants.
Conditions
- ADHD
Interventions
SPD503-AMDrug
SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
SPD503-PMDrug
SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
PlaceboDrug
Placebo matched to Guanfacine Hydrochloride Extended Release
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)Time frame: Baseline and weekly up to 8 weeks
Locations
61 sites in 1 country. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
Melmed Center
Scottsdale, Arizona
Clinical Study Centers, LLC
Little Rock, Arkansas
Valley Clinical Research, Inc.
El Centro, California
Peninsula Research Associates
Rolling Hills Estates, California
UCSD Department of Psychiatry
San Diego, California
University of California, San Francisco
San Francisco, California
Elite Clinical Trials, Inc
Wildomar, California
Florida Clinical Research Center, LLC
Bradenton, Florida
Gulfcoast Clinical Research Center
Fort Myers, Florida
Sarkis Clinical Trials
Gainesville, Florida
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida
Florida Clinical Research Center, LLC
Maitland, Florida
Miami Children's Hospital
Miami, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Janus Center for Psychiatric Research
West Palm Beach, Florida
AMR-Baber Research, Inc.
Naperville, Illinois
American Medical Research, Inc
Oak Brook, Illinois
Goldpoint Clinical Research, LLC
Indianapolis, Indiana
Pedia Research
Newburgh, Indiana
Psychiatric Associates
Overland Park, Kansas
Vince and Associates Clinical Research
Overland Park, Kansas
Pedia Research, LLC
Owensboro, Kentucky
Marc Hertzman, MD, PC
Rockville, Maryland
Delmarva Family Resources
Salisbury, Maryland
Massachussests General Hospital
Cambridge, Massachusetts
Neurobehaviorial Medicine
Bloomfield Hills, Michigan
Rochester Center for Behavioral Medicine
Rochester Hills, Michigan
Behavioral Medicine Center
Troy, Michigan
The Center for Pharmaceutical Research
Kansas City, Missouri
Midwest Research Group/St. Charles Psychiatric Associates
Saint Charles, Missouri
Premier Psychiatric Research Inst. LLC
Lincoln, Nebraska
Centers for Psychiatry and Behavioral Medicine
Las Vegas, Nevada
Children's Specialized Hospital
Toms River, New Jersey
Bioscience Research, LLC
Mount Kisco, New York
Richmond Behavioral Associates
Staten Island, New York
Duke University Medical Center ADHD Program
Durham, North Carolina
Triangle Neuropsychiatry, PLLC
Durham, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Department of Psychiatry, The Ohio State University
Columbus, Ohio
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.